Jing Zhou

Jing Zhou

Auto-generated profile, based on publicly available information

Jing Zhou

Department of Neurology, The First People’s Hospital of Foshan, Foshan, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
XCXiaodong Chen
Xiaodong Chen
JZJing Zhou
Jing Zhou
RLRui Li
Rui Li
BZBingjun Zhang
Bingjun Zhang
YWYuge Wang
Yuge Wang
WQWei Qiu
Wei Qiu
Chen X, et al. J Clin Neurol. 2022 Jul;18(4):453-462. https://doi.org/10.3988/jcn.2022.18.4.453

16 May 2024 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
RLRui Li
Rui Li
JZJing Zhou
Jing Zhou
HWHaotian Wu
Haotian Wu
YWYuge Wang
Yuge Wang
JCJuanjuan Chen
Juanjuan Chen
Introduction The real-world data on the medium- to long-term effectiveness and safety of teriflunomide in Chinese patients with relapsing multiple sclerosis (MS) is limited. Therefore, this study aims to assess the treatment outcomes of teriflunomide in Chinese patients with MS over a medium- to long-term period. Methods This cohort study was carried out in three tertiary hospitals and regional MS centers located in the Greater Bay Area of China. We obtained the historical clinical data of patients who underwent teriflunomide treatment for at least 6 months. The primary objective was to evaluate the proportion of patients achieving no evidence of disease activity (NEDA)-3 status, which is characterized by the absence of relapses, confirmed disability worsening, and new or enlarging MRI lesions, over time. Secondary objectives included assessing the proportion of patients meeting each NEDA-3 criterion, changes in motor and cognitive function, as well as the incidence of adverse events and treatment discontinuations. Results A total of 160 patients with MS were enrolled, including 125 patients treated with teriflunomide for at least 1 year (≥ 1-year completers) and 71 patients treated for at least 2 years (≥ 2-year completers). A total of 85.63% of the overall population achieved clinical NEDA-3 status at 6 months of teriflunomide treatment, and 71.20% of ≥ 1-year completers achieved NEDA-3 status at 12 months of teriflunomide treatment. The median timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), and paced auditory serial addition test (PASAT) results were relatively stable before and after treatment. Conclusion Medium- to long-term MS disease activity, as indicated by NEDA-3 status, is well controlled in patients treated with continuous teriflunomide treatment in real-world settings.